Pascal and Francis Bibliographic Databases

Help

Search results

Your search

jo.\*:(%22The pressuremeter and its new avenues. International symposium%22)

Filter

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Document Type [dt]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Language

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Origin

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 25 of 889870

  • Page / 35595
Export

Selection :

  • and

ISCAS : 1992 IEEE international symposium on circuits and systems, San Diego CA, May 10-13, 1992International symposium on circuits and systems. 1992, issn 0277-674X, isbn 0-7803-0594-9, 6Vol, 3028 p., isbn 0-7803-0594-9Conference Proceedings

ISCAS : 1993 IEEE international symposium on circuits and systems (Chicago IL, May 3-6, 1993)International symposium on circuits and systems. 1993, issn 0277-674X, isbn 0-7803-1282-1, 4Vol, 2271 p., isbn 0-7803-1282-1Conference Proceedings

A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumorsGHAMANDE, Sharad; LIN, Chia-Chi; COLEMAN, Teresa et al.Investigational new drugs. 2014, Vol 32, Num 3, pp 445-451, issn 0167-6997, 7 p.Article

A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumorsVON MEHREN, Margaret; BRITTEN, Carolyn D; LEONG, Stephen et al.Investigational new drugs. 2014, Vol 32, Num 3, pp 518-525, issn 0167-6997, 8 p.Article

Design of informative renal impairment studies: evaluation of the impact of design stratification on bias, precision and dose adjustment errorCOEN VAN HASSELT, J. G; SCHELLENS, Jan H. M; BEIJNEN, Jos H et al.Investigational new drugs. 2014, Vol 32, Num 5, pp 913-927, issn 0167-6997, 15 p.Article

Differences in maximum tolerated doses and approval doses of molecularly targeted oncology drug between Japan and Western countriesMAEDA, Hideki; KUROKAWA, Tatsuo.Investigational new drugs. 2014, Vol 32, Num 4, pp 661-669, issn 0167-6997, 9 p.Article

Evaluation of two 125I-radiolabeled acridine derivatives for Auger-electron radionuclide therapy of melanomaGARDETTE, Maryline; VIALLARD, Claire; WU, Ting-Di et al.Investigational new drugs. 2014, Vol 32, Num 4, pp 587-597, issn 0167-6997, 11 p.Article

Growth hormone-releasing hormone antagonists abolish the transactivation of human epidermal growth factor receptors in advanced prostate cancer modelsMUNOZ-MORENO, Laura; ARENAS, M. Isabel; CARMENA, M. José et al.Investigational new drugs. 2014, Vol 32, Num 5, pp 871-882, issn 0167-6997, 12 p.Article

PF-03446962, a fully-human monoclonal antibody against transforming growth-factor 3 (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trialNECCHI, A; GIANNATEMPO, P; MAFFEZZINI, M et al.Investigational new drugs. 2014, Vol 32, Num 3, pp 555-560, issn 0167-6997, 6 p.Article

PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell linesIZETTI, Patricia; HAUTEFEUILLE, Agnes; HAINAUT, Pierre et al.Investigational new drugs. 2014, Vol 32, Num 5, pp 783-794, issn 0167-6997, 12 p.Article

Phase I and pharmacokinetic study of trabectedin, a DNA minor groove binder administered as a 24-h continuous infusion in Japanese patients with soft tissue sarcomaUEDA, Takafumi; KAKUNAGA, Shigeki; ANDO, Masashi et al.Investigational new drugs. 2014, Vol 32, Num 4, pp 691-699, issn 0167-6997, 9 p.Article

Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancerBRITTEN, Carolyn D; ADJEI, Alex A; MILLHAM, Robert et al.Investigational new drugs. 2014, Vol 32, Num 3, pp 510-517, issn 0167-6997, 8 p.Article

Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomachOCEAN, Allyson J; CHRISTOS, Paul; BESANCENEY-WEBLER, Christen et al.Investigational new drugs. 2014, Vol 32, Num 3, pp 542-548, issn 0167-6997, 7 p.Article

Ring-substituted analogs of 3,3'-diindolylmethane (DIM) induce apoptosis and necrosis in androgen-dependent and -independent prostate cancer cellsGOLDBERG, A. A; TITORENKO, V. I; BEACH, A et al.Investigational new drugs. 2014, Vol 32, Num 1, pp 25-36, issn 0167-6997, 12 p.Article

Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II studyLORIOT, Yohann; FIZAZI, Karim; HOLTKAMP, Gertjan M et al.Investigational new drugs. 2014, Vol 32, Num 5, pp 995-1004, issn 0167-6997, 10 p.Article

The ability of molecular docking to unravel the controversy and challenges related to P-glycoprotein—a well-known, yet poorly understood drug transporterZEINO, Maen; SAEED, Mohamed E. M; KADIOGLU, Onat et al.Investigational new drugs. 2014, Vol 32, Num 4, pp 618-625, issn 0167-6997, 8 p.Article

The combination of RAF265, SB590885, ZSTK474 on thyroid cancer cell lines deeply impact on proliferation and MAPK and PI3K/Akt signaling pathwaysBAROLLO, Susi; BERTAZZA, Loris; BALDINI, Enke et al.Investigational new drugs. 2014, Vol 32, Num 4, pp 626-635, issn 0167-6997, 10 p.Article

Improved replication efficiency of echovirus 5 after transfection of colon cancer cells using an authentic 5' RNA genome end methodologyISRAELSSON, S; SÄVNEBY, A; EKSTRÖM, J.-O et al.Investigational new drugs. 2014, Vol 32, Num 6, pp 1063-1070, issn 0167-6997, 8 p.Article

Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinomaTANNIR, Nizar M; FORERO-TORRES, Andres; GARTNER, Elaina M et al.Investigational new drugs. 2014, Vol 32, Num 6, pp 1246-1257, issn 0167-6997, 12 p.Article

Pneumocystis jirovecii pneumonia under everolimus in two patients with metastatic pancreatic neuroendocrine tumorsCARBONNAUX, Mélodie; MOLIN, Yann; SOUQUET, Pierre-Jean et al.Investigational new drugs. 2014, Vol 32, Num 6, pp 1308-1310, issn 0167-6997, 3 p.Article

A phase I study of S-1 with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancerHASEGAWA, Yoshikazu; OKAMOTO, Isamu; AZUMA, Koichi et al.Investigational new drugs. 2013, Vol 31, Num 3, pp 599-604, issn 0167-6997, 6 p.Article

A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance)GUPTA, Pankaj; MULKEY, Flora; LARSON, Richard A et al.Investigational new drugs. 2013, Vol 31, Num 5, pp 1311-1320, issn 0167-6997, 10 p.Article

A preclinical and clinical study of mycophenolate mofetil in pancreatic cancerRODRIGUEZ-PASCUAL, J; SHA, P; GARCIA-GARCIA, E et al.Investigational new drugs. 2013, Vol 31, Num 1, pp 14-19, issn 0167-6997, 6 p.Article

Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell linesMA, Brigette B. Y; LUI, Vivian W. Y; SAI WAI TSAO et al.Investigational new drugs. 2013, Vol 31, Num 1, pp 30-38, issn 0167-6997, 9 p.Article

Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II studyHYAMS, David M; CHAN, Arlene; BROWN, Kathryn et al.Investigational new drugs. 2013, Vol 31, Num 5, pp 1345-1354, issn 0167-6997, 10 p.Article

  • Page / 35595